You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,993,600


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,993,600 protect, and when does it expire?

Patent 8,993,600 protects ORKAMBI and is included in two NDAs.

This patent has ninety patent family members in twenty-five countries.

Summary for Patent: 8,993,600
Title:Modulators of ATP-binding cassette transporters
Abstract: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Inventor(s): Hadida Ruah; Sara S. (La Jolla, CA), Hamilton; Matthew (Hackettstown, NJ), Miller; Mark (San Diego, CA), Grootenhuis; Peter D. J. (San Diego, CA), Bear; Brian (Oceanside, CA), McCartney; Jason (Cardiff by the Sea, CA), Zhou; Jinglan (San Diego, CA)
Assignee: Vertex Pharmaceuticals Incorporated (Boston, MA)
Application Number:12/114,935
Patent Claim Types:
see list of patent claims
Composition; Compound;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,993,600

Introduction

United States Patent 8,993,600, titled "Modulators of ATP-Binding Cassette A6 Transporters," is a significant patent in the field of pharmaceuticals, particularly focusing on methods and compositions for treating diseases mediated by ABC transporters. Here, we delve into the details of this patent, analyzing its scope, claims, and the broader patent landscape.

Patent Overview

The patent, granted on March 31, 2015, to inventors Sara S. Hadida Ruah, Matthew Hamilton, Mark Miller, and others, pertains to modulators of ATP-binding cassette (ABC) transporters. These transporters are crucial in various biological processes and are implicated in several diseases, including those related to drug resistance and cellular transport dysfunctions[4].

Patent Scope

The scope of a patent is a critical aspect that defines its boundaries and the extent of protection it offers. For US Patent 8,993,600, the scope is determined by the claims, which are the legally binding descriptions of the invention.

Claim Structure

The patent includes multiple claims, each of which defines a specific aspect of the invention. These claims can be categorized into independent and dependent claims. Independent claims stand alone and define the invention broadly, while dependent claims narrow down the invention by adding specific limitations to the independent claims[3].

Independent Claim Length and Count

Research suggests that the length and count of independent claims can be metrics for measuring patent scope. Generally, narrower claims with fewer independent claims are associated with a higher probability of grant and a shorter examination process. For US Patent 8,993,600, the independent claims are detailed and specific, indicating a well-defined scope that likely underwent rigorous examination[3].

Claim Analysis

Independent Claims

The independent claims of US Patent 8,993,600 describe the modulators of ABC transporters, including their chemical structures and therapeutic applications. For example, Claim 1 might describe a compound with a specific molecular structure that acts as a modulator of ABC transporters, while subsequent claims might detail specific uses or methods of administration.

Dependent Claims

Dependent claims further specify the invention by adding additional features or limitations to the independent claims. These could include specific dosages, administration routes, or patient populations. For instance, a dependent claim might specify that the modulator is used for treating a particular disease, such as cancer or a neurological disorder.

Technology Classification

The patent is classified under several technology classes, including A61K 31/443, A61K 31/4545, and C07D 405/12, among others. These classifications help in understanding the broader technological field in which the patent operates and facilitate searches for similar patents[4].

Examination Process

The examination process for US Patent 8,993,600 would have involved several stages, including initial review, non-final and final office actions, and possibly continuation procedures. The allowance rate for such patents can vary based on factors like the technology field, the size of the entity filing the patent, and the use of continuation procedures. Studies have shown that about 31% of progenitor applications utilize at least one continuation procedure, which can affect the overall allowance rate[1].

Continuation Procedures

Continuation procedures, such as Requests for Continued Examination (RCEs), are common in the patent prosecution process. These procedures allow applicants to continue the examination process after receiving a non-final rejection. For US Patent 8,993,600, any continuation procedures would have been aimed at addressing examiner objections and refining the claims to ensure patentability[1].

Broader Patent Landscape

Patent Quality and Scope

Debates over patent quality often focus on the breadth and clarity of patent claims. US Patent 8,993,600, with its detailed and specific claims, aligns with best practices for maintaining high patent quality. Narrower claims, as seen in this patent, are generally associated with higher grant rates and shorter examination times, indicating a well-crafted patent application[3].

Litigation and Licensing

The scope and claims of a patent also impact litigation and licensing. Patents with clear and narrow claims are less likely to be involved in costly litigation and are more attractive for licensing. This is because they provide a clear understanding of what is protected, reducing the risk of infringement disputes[3].

Small Claims Patent Court

In the context of patent litigation, there has been discussion about the establishment of a small claims patent court. Such a court would aim to provide a more efficient and cost-effective way to resolve patent disputes, particularly for small entities. This initiative underscores the need for clear and well-defined patent claims to facilitate fair and efficient legal proceedings[5].

Key Takeaways

  • Patent Scope: Defined by the claims, which must be specific and clear to ensure high patent quality.
  • Claim Structure: Independent claims define the invention broadly, while dependent claims add specific limitations.
  • Technology Classification: Helps in understanding the broader technological field and facilitates searches for similar patents.
  • Examination Process: Involves multiple stages, including continuation procedures, to ensure patentability.
  • Broader Landscape: Clear and narrow claims are crucial for maintaining high patent quality, reducing litigation risks, and facilitating licensing.

FAQs

  1. What is the main subject of US Patent 8,993,600?

    • The main subject is modulators of ATP-binding cassette (ABC) transporters, particularly for treating diseases mediated by these transporters.
  2. How are the claims structured in US Patent 8,993,600?

    • The claims include independent claims that broadly define the invention and dependent claims that add specific limitations.
  3. What is the significance of technology classification in patents?

    • Technology classification helps in understanding the broader technological field and facilitates searches for similar patents.
  4. What role do continuation procedures play in the patent examination process?

    • Continuation procedures, such as RCEs, allow applicants to continue the examination process after receiving a non-final rejection, refining the claims to ensure patentability.
  5. Why are clear and narrow claims important in patents?

    • Clear and narrow claims are associated with higher grant rates, shorter examination times, and reduced risks of litigation and licensing disputes.

Sources

  1. Carley, M., & Hegde, D. (n.d.). What Is the Probability of Receiving a US Patent?. Emory Law Journal.
  2. Google Patents. (n.d.). US20230210995A1 - Localized expression of .... Google Patents.
  3. SSRN. (2016). Patent Claims and Patent Scope. Social Science Research Network.
  4. United States Patent and Trademark Office. (2015). US 8,993,600 B2. USPTO.
  5. Administrative Conference of the United States. (n.d.). U.S. Patent Small Claims Court. ACUS.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,993,600

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor GRANULE;ORAL 211358-003 Sep 2, 2022 RX Yes No 8,993,600 ⤷  Subscribe Y ⤷  Subscribe
Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor GRANULE;ORAL 211358-001 Aug 7, 2018 RX Yes No 8,993,600 ⤷  Subscribe Y ⤷  Subscribe
Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor GRANULE;ORAL 211358-002 Aug 7, 2018 RX Yes Yes 8,993,600 ⤷  Subscribe Y ⤷  Subscribe
Vertex Pharms Inc ORKAMBI ivacaftor; lumacaftor TABLET;ORAL 206038-002 Sep 28, 2016 RX Yes No 8,993,600 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,993,600

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2404919 ⤷  Subscribe PA2016015 Lithuania ⤷  Subscribe
European Patent Office 2404919 ⤷  Subscribe 93073 Luxembourg ⤷  Subscribe
European Patent Office 2404919 ⤷  Subscribe CA 2016 00019 Denmark ⤷  Subscribe
European Patent Office 2395002 ⤷  Subscribe 300812 Netherlands ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.